Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Santaris Pharma A/S

http://www.santaris.com/

Latest From Santaris Pharma A/S

Novartis Slips Into Pfizer's Number One Pharma Slot Amid Leaderboard Shakeup

Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.

Outlook 2022 Commercial

FDA’s New Orphan Products Director Brings Industry, Legal, Academic, Regulatory Background

Sandra Retzky worked at AstraZeneca and in Delaware's Medicaid fraud unit before joining the US FDA in 2016.

Leadership Rare Diseases

136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure

The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.

Companies Business Strategies

Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds

Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.

Emerging Company Profile Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register